SPL.AX - Starpharma Holdings Limited

ASX - ASX Delayed Price. Currency in AUD
1.2900
-0.0300 (-2.27%)
As of 11:45AM AEST. Market open.
Stock chart is not supported by your current browser
Previous Close1.3200
Open1.3200
Bid1.2900 x 0
Ask1.2950 x 0
Day's Range1.2900 - 1.3200
52 Week Range0.8700 - 1.6620
Volume87,264
Avg. Volume417,083
Market Cap479.485M
Beta (3Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.0330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1988-03-25
1y Target Est1.44
  • Business Wire14 days ago

    Starpharma Signs Second Oncology Agreement With AstraZeneca

    Starpharma has signed a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP®) version of one of AstraZeneca’s major marketed oncology medicines. Following completion of agreed preclinical studies by Starpharma, AstraZeneca has the option to licence the DEP® oncology drug candidate for an option exercise fee of US$5M, plus industry standard development and commercialisation milestones and escalating royalties on sales.

  • Should You Worry About Starpharma Holdings Limited's (ASX:SPL) CEO Pay Cheque?
    Simply Wall St.2 months ago

    Should You Worry About Starpharma Holdings Limited's (ASX:SPL) CEO Pay Cheque?

    In 2006 Jackie Fairley was appointed CEO of Starpharma Holdings Limited (ASX:SPL). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider...

  • Who Has Been Buying Starpharma Holdings Limited (ASX:SPL) Shares?
    Simply Wall St.5 months ago

    Who Has Been Buying Starpharma Holdings Limited (ASX:SPL) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...

  • Business Wire5 months ago

    VivaGel® Condom Receives Final Regulatory Approval in Japan

    Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel® condom has received final regulatory approval and is now able to be marketed in Japan, following the completion of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) review of the product's medical device classification and associated data. This final approval follows on from the previously granted regulatory certification, which was attained for the VivaGel® condom. Starpharma has worked closely with its commercial partner for Japan, Okamoto Industries (Okamoto), throughout the regulatory process.

  • Simply Wall St.7 months ago

    Could The Starpharma Holdings Limited (ASX:SPL) Ownership Structure Tell Us Something Useful?

    A look at the shareholders of Starpharma Holdings Limited (ASX:SPL) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...

  • Business Wirelast year

    Starpharma Licenses VivaGel® BV to Mundipharma for Europe

    Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a licence agreement for the sales and marketing rights to VivaGel® BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America.